Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02606461 · ClinicalTrials.gov registry record · Phase 2
Selinexor in Advanced Liposarcoma
A Phase 2 study, sponsored by Karyopharm Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 342
- Enrollment target
NCT02606461 is a Phase 2 study that has completed, run by Karyopharm Therapeutics. The registered enrollment target is 342 participants.
The verdict
NCT02606461, a Phase 2 study, has completed, sponsored by Karyopharm Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 342 participants
- Enrollment target
Study Summary
This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 342 total patients will be randomized to study treatment (selinexor or placebo).
Interventions
- DRUG Placebo
- DRUG Selinexor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2016-01-04 |
| Est. Completion | 2021-10-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02606461
The ClinicalTrials.gov registry entry for NCT02606461 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 342 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Karyopharm Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02606461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02606461 about?
NCT02606461 is a clinical study titled "Selinexor in Advanced Liposarcoma". This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 342 total patients will be randomized to study treatment (selinexor or placebo).
What is the current status of trial NCT02606461?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 342 participants. The study started on 2016-01-04. Estimated completion is 2021-10-26.
What interventions are being tested in trial NCT02606461?
The interventions under investigation include: Placebo (DRUG), Selinexor (DRUG).
Who is sponsoring clinical trial NCT02606461?
This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.